These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 1348978

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E, Bomanji J, Mather SJ, Britton KE, Wass JA, Grossman AB, Besser GM.
    Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
    Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N.
    J Endocrinol Invest; 1997 May; 20(7):424-8. PubMed ID: 9309542
    [Abstract] [Full Text] [Related]

  • 7. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
    Görges R, Cordes U, Engelbach M, Bartelt KM, Haberern G, Hey O, Beyer J, Bockisch A.
    Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
    [Abstract] [Full Text] [Related]

  • 8. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status.
    Reubi JC, Landolt AM.
    J Clin Endocrinol Metab; 1989 Apr; 68(4):844-50. PubMed ID: 2537844
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).
    Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, Sara R, Bonino C, Lunghi F.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):850-6. PubMed ID: 1653785
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
    Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E.
    Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
    [Abstract] [Full Text] [Related]

  • 16. 111In-octreotide scintigraphy in oncology.
    Krenning EP, Kwekkeboom DJ, Reubi JC, Van Hagen PM, van Eijck CH, Oei HY, Lamberts SW.
    Metabolism; 1992 Sep; 41(9 Suppl 2):83-6. PubMed ID: 1355591
    [Abstract] [Full Text] [Related]

  • 17. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.
    Horm Res; 2004 Sep; 62(5):227-32. PubMed ID: 15477693
    [Abstract] [Full Text] [Related]

  • 18. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
    Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E, Songini C, Fazio F, Beck-Peccoz P, Giovanelli M.
    Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
    [Abstract] [Full Text] [Related]

  • 19. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L.
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [Abstract] [Full Text] [Related]

  • 20. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.